BioLineRx Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . BioLineRx
BLRX Stock  USD 3.84  0.05  1.32%   
BioLineRx's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing BioLineRx's valuation are provided below:
Gross Profit
10.2 M
Profit Margin
(0.45)
Market Capitalization
16.4 M
Enterprise Value Revenue
0.0268
Revenue
17.3 M
We have found one hundred twenty available fundamental signals for BioLineRx, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of BioLineRx prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Enterprise Value is likely to rise to about 41.9 M in 2025, whereas Market Cap is likely to drop slightly above 20.3 M in 2025.

BioLineRx Total Revenue

18.61 Million

Check BioLineRx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioLineRx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.3 M, Gross Profit of 20.7 M or Other Operating Expenses of 29.6 M, as well as many indicators such as Price To Sales Ratio of 0.7, Dividend Yield of 0.0 or PTB Ratio of 1.81. BioLineRx financial statements analysis is a perfect complement when working with BioLineRx Valuation or Volatility modules.
  
Build AI portfolio with BioLineRx Stock
Check out the analysis of BioLineRx Correlation against competitors.
For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.

BioLineRx Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets51.4 M38.9 M47.5 M
Slightly volatile
Other Current Liabilities3.3 M4.8 M2.5 M
Slightly volatile
Total Current Liabilities10.8 M15.4 M10.1 M
Slightly volatile
Total Stockholder Equity12.8 M13.5 M30.8 M
Very volatile
Property Plant And Equipment Net2 M1.4 M2 M
Slightly volatile
Accounts Payable5.1 M5.6 M5 M
Slightly volatile
Cash9.1 M10.4 M9 M
Pretty Stable
Non Current Assets Total11.8 M11.8 M11.8 M
Slightly volatile
Cash And Short Term Investments37.2 M19.6 M34.1 M
Slightly volatile
Net Receivables4.1 M3.9 M1 M
Slightly volatile
Common Stock Shares Outstanding83.9 M79.9 M23.5 M
Slightly volatile
Short Term Investments8.7 M9.1 M23.9 M
Pretty Stable
Liabilities And Stockholders Equity51.4 M38.9 M47.5 M
Slightly volatile
Non Current Liabilities Total6.3 M10 M6.1 M
Slightly volatile
Other Current Assets288.6 K534 K382.5 K
Very volatile
Other Stockholder Equity237.4 M359.1 M230 M
Slightly volatile
Total Liabilities16 M25.4 M15.4 M
Slightly volatile
Total Current Assets39.6 M27.1 M35.7 M
Slightly volatile
Accumulated Other Comprehensive Income11.8 M16.1 M11.1 M
Slightly volatile
Intangible Assets9.4 M10.4 M9.6 M
Slightly volatile
Common Stock40 M38.1 M11.5 M
Slightly volatile
Short and Long Term Debt Total15.8 M15 M5.5 M
Slightly volatile
Other Liabilities2.2 M2.1 M2 M
Pretty Stable
Other Assets0.860.986.8 K
Slightly volatile
Long Term Debt9.4 M9 M3.8 M
Slightly volatile
Short Term Debt5.3 M5 M1.7 M
Slightly volatile
Property Plant Equipment2.1 M2.6 M2 M
Slightly volatile
Current Deferred Revenue15.6 M14.9 M5.1 M
Slightly volatile
Common Stock Total Equity11.9 M11.4 M4.9 M
Slightly volatile
Property Plant And Equipment Gross3.4 M6.3 M3 M
Slightly volatile
Net Tangible Assets22.1 M41.7 M27.5 M
Slightly volatile
Short and Long Term Debt4.7 M4.5 M1.5 M
Slightly volatile
Net Invested Capital35.5 M26.9 M47.6 M
Slightly volatile
Net Working Capital21.4 M11.7 M33.8 M
Slightly volatile
Capital Stock21.3 M38.1 M11.3 M
Slightly volatile
Long Term Debt Total6 M6.8 M7.4 M
Slightly volatile
Capital Surpluse212.8 M239.3 M261 M
Slightly volatile
Capital Lease Obligations1.5 M1.6 M1.9 M
Slightly volatile

BioLineRx Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4.3 M4.1 M1 M
Slightly volatile
Other Operating Expenses29.6 M49.3 M26.6 M
Slightly volatile
Research Development13.2 M9.1 M16 M
Pretty Stable
Total Operating Expenses27.8 M40.1 M25.7 M
Slightly volatile
Interest Expense9.5 M9.1 M1.8 M
Slightly volatile
Selling General Administrative19.4 M18.5 M6.6 M
Slightly volatile
Selling And Marketing Expenses10.6 M10.1 M3.5 M
Slightly volatile
Interest Income1.1 M1.8 M1.2 M
Slightly volatile
Reconciled Depreciation4.3 M4.1 M1.1 M
Slightly volatile

BioLineRx Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation4.3 M4.1 M1.1 M
Slightly volatile
Capital Expenditures51.3 K54 K1.2 M
Very volatile
End Period Cash Flow9.1 M10.4 M9 M
Pretty Stable
Begin Period Cash Flow4 M4.3 M9.9 M
Slightly volatile
Stock Based Compensation1.6 M1.1 M1.5 M
Slightly volatile
Sale Purchase Of Stock16.2 M18.3 M18.9 M
Very volatile
Issuance Of Capital Stock22.1 M16.4 M12.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.70.738517.9413
Pretty Stable
PTB Ratio1.811.58782.199
Very volatile
Days Sales Outstanding56.4148.721353.6785
Pretty Stable
Book Value Per Share0.01070.01120.5667
Slightly volatile
Average Payables2.2 M2.5 M2.7 M
Slightly volatile
Stock Based Compensation To Revenue0.03730.03920.4013
Pretty Stable
Capex To Depreciation0.01260.01332.4007
Very volatile
PB Ratio1.811.58782.199
Very volatile
EV To Sales0.850.897620.4349
Slightly volatile
Inventory Turnover1.942.94531.9595
Slightly volatile
Days Of Inventory On Hand174124188
Slightly volatile
Payables Turnover1.741.65910.5097
Slightly volatile
Sales General And Administrative To Revenue1.130.63792.9348
Pretty Stable
Research And Ddevelopement To Revenue0.30.31612.188
Pretty Stable
Capex To Revenue0.00180.00190.0518
Slightly volatile
Cash Per Share0.01550.01630.6396
Slightly volatile
Days Payables Outstanding209220967
Slightly volatile
Income Quality5.04.75791.7117
Pretty Stable
Intangibles To Total Assets0.140.26860.164
Slightly volatile
Current Ratio1.671.75935.444
Slightly volatile
Receivables Turnover5.717.49166.7573
Pretty Stable
Shareholders Equity Per Share0.01070.01120.5667
Slightly volatile
Debt To Equity1.171.11730.2751
Slightly volatile
Capex Per Share0.00.00.0184
Slightly volatile
Revenue Per Share0.02290.02420.1684
Slightly volatile
Interest Debt Per Share0.03120.02010.033
Pretty Stable
Debt To Assets0.410.38660.1098
Slightly volatile
Operating Cycle231173241
Slightly volatile
Price Book Value Ratio1.811.58782.199
Very volatile
Days Of Payables Outstanding209220967
Slightly volatile
Ebt Per Ebit0.730.45180.8971
Very volatile
Company Equity Multiplier3.032.89031.8113
Slightly volatile
Long Term Debt To Capitalization0.420.39960.1189
Slightly volatile
Total Debt To Capitalization0.550.52770.1581
Slightly volatile
Debt Equity Ratio1.171.11730.2751
Slightly volatile
Quick Ratio1.481.55526.6573
Slightly volatile
Net Income Per E B T1.090.961.0199
Slightly volatile
Cash Ratio0.640.67741.2401
Slightly volatile
Days Of Inventory Outstanding174124188
Slightly volatile
Days Of Sales Outstanding56.4148.721353.6785
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.851.00121.0442
Pretty Stable
Price To Book Ratio1.811.58782.199
Very volatile
Fixed Asset Turnover22.4621.38954.9652
Slightly volatile
Debt Ratio0.410.38660.1098
Slightly volatile
Price Sales Ratio0.70.738517.9413
Pretty Stable
Asset Turnover0.780.74380.1609
Slightly volatile
Gross Profit Margin0.620.67990.3172
Pretty Stable
Price Fair Value1.811.58782.199
Very volatile

BioLineRx Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap20.3 M21.4 M57.1 M
Pretty Stable
Enterprise Value41.9 M26 M50.3 M
Pretty Stable

BioLineRx Fundamental Market Drivers

Forward Price Earnings93.4579
Cash And Short Term Investments19.6 M

BioLineRx Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
22nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About BioLineRx Financial Statements

BioLineRx investors use historical fundamental indicators, such as BioLineRx's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioLineRx. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue14.9 M15.6 M
Cost Of Revenue9.3 M9.7 M
Total Revenue28.9 M18.6 M
Stock Based Compensation To Revenue 0.04  0.04 
Sales General And Administrative To Revenue 0.64  1.13 
Research And Ddevelopement To Revenue 0.32  0.30 
Revenue Per Share 0.02  0.02 
Ebit Per Revenue(0.71)(0.74)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
NOAHNoah Holdings
CIGCompanhia Energetica de
BBVABanco Bilbao Viscaya

Additional Tools for BioLineRx Stock Analysis

When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY